Abstract
Background:
Androgen deprivation therapy (ADT) in prostate cancer (PCa) has been associated with development of insulin resistance. However, the predominant site of insulin resistance remains unclear.
Methods:
The ADT & Metabolism Study was a single-center, 24-week, prospective observational study that enrolled ADT-naïve men without diabetes who were starting ADT for at least 24 weeks (ADT group, n=42). The control group comprised men without diabetes with prior history of PCa who were in remission after prostatectomy (non-ADT group, n=23). Prevalent diabetes mellitus was excluded in both groups using all three laboratory criteria defined in the American Diabetes Association guidelines. All participants were eugonadal at enrollment. The primary outcome was to elucidate the predominant site of insulin resistance (liver or skeletal muscle). Secondary outcomes included assessments of body composition, and hepatic and intramyocellular fat. Outcomes were assessed at baseline, 12, and 24 weeks.
Results:
At 24 weeks, there was no change in hepatic (1.2; 95% confidence interval [CI], −2.10–4.43; p=0.47) or skeletal muscle (−3.2; 95% CI, −7.07–0.66; p=0.10) insulin resistance in the ADT group. No increase in hepatic or intramyocellular fat deposition or worsening of glucose was seen. These changes were mirrored by those observed in the non-ADT group. Men undergoing ADT gained 3.7 kg of fat mass.
Conclusions:
In men with PCa and no diabetes, 24 weeks of ADT did not change insulin resistance despite adverse body composition changes. These findings should be reassuring for treating physicians and for patients who are being considered for short-term ADT.
Keywords: Androgen deprivation therapy, Insulin resistance, Cardiovascular disease, Hypogonadism, body composition
Precis:
In this prospective study of hormone-naïve men who were eugonadal and did not have diabetes, 24 weeks of androgen deprivation therapy (ADT) for prostate cancer (PCa) was not associated with worsening of hepatic or skeletal muscle insulin resistance despite a substantial increase in fat mass. These findings have relevance for both physicians and patients when determining treatment for PCa and suggest that a short course of ADT may not worsen metabolic risk in patients without pre-existing diabetes.
INTRODUCTION
Prostate cancer (PCa) is the most common solid cancer in men in the United States1. At initial diagnosis, most men have organ-confined disease and are generally managed with surveillance or local approaches including prostatectomy and radiation. Since the prostate is an androgen-dependent organ, androgen deprivation therapy (ADT) remains the cornerstone of treatment in patients with locally advanced, recurrent, or metastatic disease2, with most men receiving ADT for at least 24-weeks. Androgen deprivation is achieved via treatment with gonadotropin-releasing hormone (GnRH) agonists or antagonists, resulting in castrate levels of serum testosterone (<50 ng/dL). The resulting profound androgen deficiency leads to increased fat mass, which is likely the inciting event in the development of insulin resistance, an established risk factor for diabetes and cardiovascular disease (CVD)3–5. Previous data suggest that development of insulin resistance during ADT displays an accelerated course and occurs within weeks of treatment initiation6. Indeed, men receiving ADT, compared with those not receiving ADT, have a higher risk of incident diabetes, coronary artery disease, myocardial infarction, and cardiovascular mortality7, raising concerns among clinicians about administering ADT to men with prevalent or at a high-risk of CVD, with patients often referred for extensive cardiac evaluation before treatment initiation8.
Systemic insulin resistance is a sum of insulin resistance in different organs, predominantly in the liver and skeletal muscle9,10. Although the occurrence of insulin resistance during ADT has been reported, the site of its predominant expression (muscle or liver) remains unclear. Additionally, the mechanisms leading to insulin resistance have also not been elucidated, which could guide pharmacotherapy with tissue-selective insulin sensitizers to prevent its development. The ADT & Metabolism Study was designed to address these knowledge gaps and overcome the limitations of previous studies.
MATERIALS AND METHODS
Design and Participants
The ADT & Metabolism Study was funded by the National Cancer Institute (5R01CA226211). The study design has been reported previously11 and briefly described below. The study protocol was approved by the Institutional Review Board of the Dana-Farber Cancer Institute before enrollment of study participants.
This was a single-center, 24-week, prospective observational study that enrolled treatment-naïve (no prior ADT) adult men with PCa who were about to undergo ADT with GnRH agonists or antagonists for at least 24 weeks (ADT group). The control group comprised men with prior prostatectomy for localized PCa who were in remission and had never received ADT (non-ADT group). Participants were recruited from oncology and urology clinics at the Dana Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts, USA. Enrollment commenced in February 2019, and the final participant completed the study in June 2022.
Eligibility Criteria
The study enrolled men aged 19 years and older. As the primary outcome was to determine the specific site of insulin resistance during ADT, a rigorous process was implemented to carefully exclude men with prevalent diabetes mellitus. Thus, participants with a known diagnosis of diabetes or those taking antidiabetic medications were excluded during phone screening. At the in-person screening visit, labs were drawn after an overnight fast and participants with glucose level ≥126 mg/dL or glycated hemoglobin (HbA1c) level >6.5% were excluded. Participants also underwent frequent-sampling 75-g oral glucose tolerance test (OGTT), and those with glucose level ≥200 mg/dL at 2 hours were also excluded. Thus, subjects could only participate if they did not have prevalent diabetes based on all three laboratory criteria defined in the American Diabetes Association guidelines12. Participants with a prior history of hypogonadism and current use of systemic glucocorticoids were also excluded.
Study Visits
At baseline visit, eligible participants underwent anthropometric and electrocardiographic assessments, physical examination, assessment of body composition with dual X-ray absorptiometry (DXA) scan, and measurements of fasting lipid profile, high-sensitivity C-reactive protein (hsCRP), total and free testosterone, luteinizing hormone (LH), sex-hormone binding globulin (SHBG), and prostate-specific antigen (PSA) . Participants without contraindications to magnetic resonance imaging (MRI) were scheduled for an additional fasting visit during which magnetic resonance spectroscopy (MRS) was performed to assess intrahepatic and intramyocellular (gastrocnemius and tibialis anterior) fat. For the ADT group, the 12- and 24-week follow-up visits were timed from the ADT initiation date; for the non-ADT group, these visits were timed from the baseline visit.
STUDY OUTCOMES
Primary Outcome
The main aim of the study was to determine the predominant site of insulin resistance (liver or skeletal muscle) in men undergoing ADT. Insulin resistance was determined using frequent sampling OGTT based on the technique developed by Matsuda & DeFronzo13 and Abdul-Ghani et al14 to quantify “tissue-specific” insulin resistance, a method validated against the hyperinsulinemic euglycemic clamp technique, but less burdensome for study participants. The procedure entails collection of samples for fasting glucose and insulin at −30, −15, and 0 minutes followed by administration of 75 g of oral glucose and collection of glucose and insulin samples at 30, 60, 90, and 120 minutes. Plasma glucose was quantified using Beckman Glucose Analyzer and serum insulin was measured using high-sensitivity sandwich enzyme-linked immunosorbent assay (ELISA).
Determination of Hepatic and Skeletal Muscle Insulin Resistance:
The glucose load administered during the OGTT is followed by a rise in plasma glucose concentrations, which, in turn, stimulates insulin secretion by pancreatic beta cells. In individuals with normal insulin sensitivity, this insulin secretion suppresses hepatic glucose output during the first 30 minutes of the test and triggers glucose disposal into peripheral tissues, mainly the skeletal muscle. In subjects with hepatic insulin resistance, insulin fails to suppress hepatic glucose output efficiently, resulting in higher peak plasma glucose levels (i.e., a sum of endogenous and exogenous glucose) during the first 30 minutes of the OGTT; the magnitude of the rise in plasma glucose and insulin concentrations during this period reflects the degree of hepatic insulin resistance. Subjects with normal skeletal muscle insulin sensitivity, the glucose peak is followed by a steady decline, suggesting normal peripheral glucose disposal. In contrast, in subjects with skeletal muscle insulin resistance, insulin secretion efficiently suppresses hepatic glucose output during the first 30 minutes of the OGTT, but peripheral glucose disposal is impaired, reflected by a slower decline in glucose levels from peak value.
Following validated methods14,15, we quantified participants’ hepatic insulin resistance at each visit using the square root of the product of the area under the curve (AUC) in insulin and glucose concentrations plotted over time (in hours), limiting attention to the first 30 minutes of the OGTT. Higher product reflects greater hepatic insulin resistance, reported here as hepatic insulin resistance index (HIRI)15. Skeletal muscle insulin resistance was assessed based on the rate of decline of plasma glucose during OGTT, computed as the slope of the least square fit to the decline in plasma glucose concentration from peak divided by the mean plasma insulin concentration during this period14. Slower decline of plasma glucose reflects greater skeletal muscle insulin resistance, reported here as muscle insulin sensitivity index (MISI). The original methodology of measuring MISI has been adapted to a validated calculator 16, which was used to compute MISI. Each participant’s observed difference in HIRI and MISI from baseline to 12 and 24 weeks was computed, and analyses were performed on the resulting change scores.
In addition to the methods described above, we also assessed total body insulin resistance using surrogate methods i.e., homeostatic model of assessment for insulin resistance (HOMAIR)17 and triglyceride/HDL ratio.
Secondary Outcomes
The participants underwent MRS with a 3-Tesla MRI scanner (SkyraVE11C; Siemens AG, Erlangen, Germany) for measurement of hepatic and intramyocellular fat18,19. To assess intrahepatic fat, participants were imaged headfirst using a phased array torso coil centered at the liver and voxels were acquired avoiding vasculature and non-hepatic structures. Using breath-held single-voxel spectroscopy, hepatic lipid content was determined from the relative percentage of the spectral peak at 1.3 ppm (representing the sum of triglyceride acyl chains) over the spectral peak of protons from hepatic water at 4.7 ppm. Skeletal muscle spectroscopy was acquired using a knee coil and axial T1-weighted images were acquired with and without fat suppression from the gastrocnemius and tibialis anterior muscles after ensuring that the participant’s leg was parallel to the bore for optimal separation of the resonances for intramyocellular (IMCL) and extramyocellular (EMCL) lipid content. Both liver and muscle scans were processed using automated time-domain-based spectral fitting software (LCModel v6.3, Provencher).
Body composition was assessed using DXA (Hologic QDR 4500A; Hologic, Inc., Bedford, Massachusetts, USA). Total and free testosterone were measured using liquid chromatography-tandem mass spectrometry (sensitivity of 2 ng/dL) and equilibrium dialysis, respectively. Concentrations of SHBG and hsCRP were measured using solid phase immunofluorometric assay and high-sensitivity sandwich ELISA, respectively.
Statistical Analysis
The primary aim was to determine whether insulin resistance occurs predominantly at the liver or skeletal muscle between baseline and 12- and 24-weeks in the ADT group. We also quantified differences between the ADT and non-ADT groups in both primary and secondary outcomes. To ensure adequate statistical power for analyses specific to the ADT group, we enrolled twice as many participants in the ADT as in the non-ADT group. Estimates of change with time and differences between groups were obtained via mixed-effects regression analysis for outcome measures obtained at baseline, 12 and 24 weeks, and by linear regression analysis for outcomes obtained only at baseline and 24 weeks (e.g., MRS). Change scores at 12 and 24 weeks (relative to baseline) were computed for each participant and the corresponding differences were used as the basis for analyses. All point estimates were accompanied by 95% confidence intervals (CIs), and hypothesis tests were evaluated at the 0.05 level.
Under the relatively conservative assumption that the correlation between baseline and follow-up would be 0.5, a total of 40 evaluable participants in the ADT group provides adequate precision to estimate mean 24-week change in hepatic insulin resistance or muscle insulin sensitivity indices to within approximately 0.32 standardized units (expressed in terms of the baseline standard deviation of the indices) using 95% CIs. An evaluable sample size of 40 participants in the ADT group and 20 in the non-ADT group would in turn provide at least 90% power to detect a standardized mean between-group difference in hepatic insulin resistance or muscle insulin sensitivity indices of at least 0.9 units. Owing to inclusion of the 12-week measurement and the expectation of serial correlation among these measurements would exceed 0.5 in practice, the power to detect within-group and between-group changes and differences would exceed that implied by these computations.
RESULTS
Participants:
We enrolled 42 men in the ADT group and 23 in the non-ADT group. The participants had a mean age of 66 years and a mean body mass index (BMI) of 28 kg/m2. Many participants had prevalent cardiovascular risk factors. All participants were eugonadal at study entry. Table 1 shows the baseline characteristics of the study participants.
Table 1.
Baseline characteristics of study participants (mean ± standard deviations)
| Non-ADT N = 23 |
ADT N = 42 |
P | |
|---|---|---|---|
|
| |||
| Demographics | |||
| Age (years) | 68.96 ± 7.60 | 65.69 ± 6.46 | 0.07 |
| Race (%) | |||
| White | 21 (91%) | 41 (98%) | |
| Black or African American | 2 (9%) | 0 | |
| Asian | 0 | 1 (2%) | |
| BMI (kg/m2) | 28.94 ± 3.84 | 28.71 ± 5.48 | 0.86 |
| Weight (kg) | 88.02 ± 12.56 | 89.14 ± 19.15 | 0.80 |
| Waist Circumference (cm) | 99.28 ± 9.80 | 100.79 ± 15.94 | 0.68 |
| Hip Circumference (cm) | 102.00 ± 6.33 | 102.05 ± 10.04 | 0.98 |
| Waist-to-Hip Ratio | 0.97 ± 0.05 | 0.98 ± 0.09 | 0.55 |
| Systolic blood pressure (mmHg) | 124.70 ± 11.71 | 128.48 ± 13.98 | 0.28 |
| Diastolic blood pressure (mmHg) | 77.48 ± 8.16 | 80.00 ± 7.62 | 0.22 |
| Medical History (%) | |||
| Cardiovascular Disease | 5 (22%) | 6 (14%) | |
| Hypertension | 7 (30%) | 22 (52%) | |
| Hyperlipidemia | 16 (69%) | 19 (45%) | |
| Statin Use | 15 (65%) | 18 (43%) | |
| Obstructive Sleep Apnea | 7 (30%) | 9 (21%) | |
| Type of ADT (%) | |||
| GnRH Agonists | 40 (95%) | ||
| GnRH Antagonists | 2 (5%) | ||
| Muscle and Hepatic Insulin Resistance Indices | |||
| Hepatic Insulin Resistance Index (HIRI) | 29.53 ± 9.16 | 29.02 ± 14.89 | 0.89 |
| Muscle Insulin Sensitivity Index (MISI) (Maastricht scale) | 18.3 ± 15.7 | 24.2 ± 18.2 | 0.17 |
| Metabolic Profile (fasting) | |||
| HbA1c (%) | 5.44 ± 0.33 | 5.35 ± 0.26 | 0.21 |
| Glucose (mg/dL) | 94.30 ± 8.42 | 94.52 ± 8.33 | 0.92 |
| Insulin (μIU/mL) | 7.08 ± 5.31 | 8.36 ± 7.52 | 0.47 |
| HOMAIR | 1.58 ± 1.37 | 1.60 ± 1.60 | 0.94 |
| 2-hr Glucose (mg/dl) on baseline OGTT | 121.8 ± 33.9 | 127.2 ± 34.8 | 0.55 |
| Triglycerides/HDL ratio | 2.21 ± 1.13 | 1.79 ± 0.84 | 0.09 |
| Sex Hormones | |||
| Total Testosterone (ng/dL) | 451.04 ± 166.84 | 475.62 ± 153.71 | 0.55 |
| Free Testosterone (pg/mL) | 59.47 ± 21.70 | 60.29 ± 16.76 | 0.87 |
| Luteinizing Hormone (mIU/mL) | 6.63 ± 5.35 | 5.42 ± 3.42 | 0.27 |
| Sex Hormone Binding Globulin (nmol/L) | 43.39 ± 17.74 | 49.93 ± 17.64 | 0.16 |
| PSA | |||
| PSA (ng/mL) | 0.11 ± 0.06 | 5.68 ± 6.54 | <0.01 |
| Lipid Profile (fasting) | |||
| hsCRP (mg/L) | 2.12 ± 2.15 | 2.20 ± 2.21 | 0.90 |
| Total Cholesterol (mg/dL) | 164.57 ± 37.23 | 169.86 ± 34.60 | 0.57 |
| HDL Cholesterol (mg/dL) | 49.09 ± 10.72 | 54.86 ± 9.84 | 0.03 |
| LDL Cholesterol (mg/dL) | 95.74 ± 31.69 | 96.55 ± 32.64 | 0.92 |
| Non-HDL Cholesterol (mg/dL) | 115.48 ± 35.01 | 115.00 ± 34.94 | 0.96 |
| Triglycerides (mg/dL) | 99.52 ± 37.04 | 92.21 ± 32.79 | 0.42 |
|
| |||
| Body Composition (Dexa scan) | |||
| VAT Mass (g) | 855.06 ± 307.11 | 938.78 ± 460.36 | 0.55 |
| VAT Volume (cm3) | 924.49 ± 332.10 | 1014.87 ± 497.72 | 0.55 |
| VAT Area (cm2) | 177.36 ± 63.70 | 194.69 ± 95.47 | 0.55 |
| Total Fat Mass (kg) | 26.298 ± 7.097 | 30.227 ± 11.629 | 0.39 |
| Total (%) Fat | 29.89 ± 4.82 | 33.42 ± 6.50 | 0.28 |
| Total Lean Mass (kg) | 57.477 ± 6.063 | 54.782 ± 8.237 | 0.53 |
| Appendicular Lean Mass/Height2 (kg/m2) | 8.42 ± 2.18 | 7.69 ± 0.97 | 0.10 |
| MR Spectroscopy | |||
| Liver | |||
| Intrahepatic Triglyceride Content (IHTG) | 7.14 ± 7.97 | 8.44 ± 7.35 | 0.51 |
| Hepatic Polyunsaturation Index | 0.03 ± 0.04 | 0.08 ± 0.26 | 0.25 |
| Muscle | |||
| Gastroc Muscle Intramyocellular Lipid (IMCL, ×106) | 1.04 ± 2.04 | 0.85 ± 1.10 | 0.93 |
| Anttib Muscle Intramyocellular Lipid (IMCL, ×106) | 0.20 ± 0.27 | 0.21 ± 0.27 | 0.60 |
| Gastroc Muscle Extramyocellular Lipid (EMCL, ×106) | 7.65 ± 11.99 | 6.71 ± 9.56 | 0.87 |
| Anttib Muscle Extramyocellular Lipid (EMCL, ×106) | 1.19 ± 1.84 | 1.33 ± 2.21 | 0.56 |
| Gastroc Muscle Lipid Index (IMCL/EMCL) | 0.18 ± 0.21 | 0.22 ± 0.19 | 0.01 |
| Anttib Muscle Lipid Index (IMCL/EMCL) | 0.22 ± 0.12 | 0.24 ± 0.21 | 0.75 |
Sex Hormones:
Total and free testosterone concentrations decreased into the castrate range during ADT, while no appreciable changes were observed in the non-ADT group (Figure 1).
Figure 1:

Changes in total and free testosterone, luteinizing hormone, and SHBG in the two groups at 12 and 24 weeks.
Insulin Resistance Indices:
At 24 weeks, compared with baseline, there was no change in HIRI (1.2; 95% CI, −2.10–4.43; p=0.47) or MISI (−3.2; 95% CI, −7.07–0.66; p=0.10) (Figure 2). Additionally, the changes in these indices did not differ between the two groups (Figure 2).
Figure 2:

A) Change in hepatic insulin resistance in the ADT group over the course of 24 weeks. B) Between-group comparison of change in hepatic insulin resistance. C) Change in skeletal muscle insulin sensitivity in the ADT group over the course of 24 weeks. D) Between-group comparison of change in muscle insulin sensitivity.
Hepatic and Intramyocellular Fat:
ADT over 24 weeks did not result in changes in fat deposition in the hepatic parenchyma or skeletal muscle (Table 2). These changes were comparable between the groups (Table 3).
Table 2.
Change in MRS and Metabolic Parameters in the ADT group
| Change at 12 weeks | Change at 24 weeks | |||
|---|---|---|---|---|
|
| ||||
| P * | (N=23) | P * | ||
|
| ||||
| MR Spectroscopy | ||||
|
| ||||
| Intrahepatic Triglyceride Content (IHTG) | −1.15 (−3.32, 1.02) | 0.29 | ||
| Liver Polyunsaturation Index | −0.10 (−0.25, −0.05) | 0.20 | ||
| Gastroc Muscle Intramyocellular Lipid (IMCL) | −5.1E-07 (−1.0E-06, −2.4E-08) | 0.05 | ||
| Anttib Muscle Intramyocellular Lipid (IMCL) | 1.5E-07 (−7.3E-09, 2.9E-07) | 0.05 | ||
| Gastroc Muscle Extramyocellular Lipid (EMCL) | −1.7E-06 (−4.1E-06, 7.5E-07) | 0.19 | ||
| Anttib Muscle Extramyocellular Lipid (EMCL) | 1.2E-06 (−2.4E-08, 2.4E-06) | 0.07 | ||
| Gastroc Muscle Lipid Index (IMCL/EMCL) | −0.03 (−0.11, 0.05) | 0.47 | ||
| Anttib Muscle Lipid Index (IMCL/EMCL) | 0.03 (−0.04, 0.11) | 0.42 | ||
|
| ||||
| Metabolic Measures | (N=40) | (N=39) | ||
|
| ||||
| HbA1c (%) | 0.000 (−0.080, 0.080) | Non-estimable | 0.000 (−0.080, 0.080) | Non-estimable |
| HOMA-IR | 0.148 (−0.111, 0.407) | 0.26 | 0.138 (−0.197, 0.473) | 0.42 |
| hsCRP (mg/L) | −0.362 (−1.081, 0.357) | 0.36 | −0.594 (−1.246, 0.058) | 0.11 |
t test
Table 3.
Change in MRS and Metabolic Parameters, by group
| MR Spectroscopy | Non-ADT (N=19) | ADT (N=23) | Difference in differences | P * |
|---|---|---|---|---|
|
| ||||
| Change at 24 weeks | ||||
| Intrahepatic Triglyceride Content (IHTG) | 0.83 (−0.78, 2.45) | −1.15 (−3.32, 1.02) | −1.98 | 0.08 |
| Liver Polyunsaturation Index | 0.00 (−0.02, 0.02) | −0.10 (−0.25, −0.05) | −0.10 | 0.29 |
| Gastroc Muscle Intramyocellular Lipid (IMCL) | −1.1E-08 (−2.6E-07, 2.4E-07) | −5.1E-07 (−1.0E-06, −2.4E-08) | −4.99E-07 | 0.22 |
| Anttib Muscle Intramyocellular Lipid (IMCL) | 7.0E-08 (−1.1E-07, 2.5E-07) | 1.5E-07 (−7.3E-09, 2.9E-07) | 7.90E-08 | 0.08 |
| Gastroc Muscle Extramyocellular Lipid (EMCL) | 7.4E-08 (−2.5E-06, 2.6E-06) | −1.7E-06 (−4.1E-06, 7.5E-07) | −1.77E-06 | 0.89 |
| Anttib Muscle Extramyocellular Lipid (EMCL) | 7.4E-07 (−4.6E-07, 1.9E-06) | 1.2E-06 (−2.4E-08, 2.4E-06) | 4.60E-07 | 0.04 |
| Gastroc Muscle Lipid Index (IMCL/EMCL) | 0.13 (0.02, 0.23) | −0.03 (−0.11, 0.05) | −0.16 | 0.03 |
| Anttib Muscle Lipid Index (IMCL/EMCL) | 0.02 (−0.05, 0.09) | 0.03 (−0.04, 0.11) | 0.01 | 0.75 |
|
| ||||
| Metabolic Measures | Non-ADT (N=23) | ADT (N=40) | Difference in differences | P * |
|
| ||||
| Change at 12 weeks | ||||
| HbA1c (%) | 0.014 (−0.129, 0.157) | 0.000 (−0.080, 0.080) | −0.01 | Non-estimable |
| HOMA-IR | 0.019 (−0.363, 0.401) | 0.148 (−0.111, 0.407) | 0.13 | 0.48 |
| hsCRP (mg/L) | −0.084 (0.549, 0.381) | −0.362 (−1.081, 0.357) | −0.28 | 0.54 |
| Change at 24 weeks | (N=39) | |||
| HbA1c (%) | 0.000 (−0.143, 0.143) | 0.000 (−0.080, 0.080) | 0.00 | Non-estimable |
| HOMA-IR | 0.096 (−0.287, 0.479) | 0.138 (−0.197, 0.473) | 0.04 | 0.63 |
| hsCRP (mg/L) | 0.372 (−0.076, 0.820) | −0.594 (−1.246, 0.058) | −0.96 | 0.16 |
Wilcoxon rank sum test
Metabolic Parameters:
ADT was not associated with changes in glucose or insulin concentrations during OGTT over time (Figure 3). The trajectories of glucose and insulin levels during OGTT were comparable between the two groups (Figure 4). During follow-up, two participants in each group developed diabetes based on 2-hour OGTT glucose value.
Figure 3:

Glucose and insulin concentrations during OGTT at baseline, 12 and 24 weeks in the ADT group.
Figure 4:

Between-group comparisons of glucose and insulin concentrations during OGTT at baseline, 12 and 24 weeks.
Men undergoing ADT did not experience changes in HOMAIR, HbA1c, hsCRP (Table 2) or triglyceride/HDL ratio. Changes in these parameters were comparable between the two groups (Table 3).
Serum concentrations of triglycerides and total, LDL, and HDL cholesterol increased in the ADT group (Figure 5) and were greater than those observed in the non-ADT group (Figure 6).
Figure 5:

Changes in body composition and fasting lipid profile in participants undergoing ADT (VAT=visceral adipose tissue).
Figure 6:

Between-group comparisons of changes in fasting lipid profile, triglyceride/HDL ratio, and hsCRP at 12 and 24 weeks.
Body Composition and Anthropometry:
Men undergoing ADT experienced an increase of 3.7 kg of total fat mass and lost 2.3 kg of lean mass (Figure 5). Visceral fat mass, waist circumference, and BMI also increased during ADT. Body composition did not change appreciably in the non-ADT group (Figures 7 and 8).
Figure 7:

Between-group comparisons of changes in body composition at 12 and 24 weeks.
Figure 8:

Between-group comparisons of changes in anthropometric measures at 12 and 24 weeks.
Cardiovascular Adverse Events:
No major adverse cardiovascular events occurred during 24 weeks of ADT.
DISCUSSION
The present study enrolled carefully selected ADT-naïve men with PCa who were eugonadal and did not have diabetes to determine the predominant site of insulin resistance that may be induced by ADT. We observed that 24 weeks of ADT was not associated with worsening of hepatic or skeletal muscle insulin resistance despite a significant increase in fat mass. Previous studies had reported development of insulin resistance within a few weeks of starting ADT6, and this accelerated course was attributed to adverse changes in body composition20,21. However, the predominant site of insulin resistance (liver or skeletal muscle) had remained unclear, and its elucidation was important as initiation of appropriate insulin sensitizing medications would be beneficial in lowering cardiovascular risk in these patients. Additionally, previous studies had shortcomings as they enrolled participants in whom underlying diabetes mellitus was not rigorously excluded, suggesting that hyperinsulinemia observed in such participants may have been in response to occult diabetes. Furthermore, prior studies had assessed insulin resistance by less precise methods, such as HOMAIR. The present study shows that 24 weeks of ADT, the usual treatment duration in intermediate-risk PCa, does not worsen insulin resistance in men without pre-existing diabetes, suggesting that these patients may not be prone to developing this cardiovascular risk factor.
Adverse changes in body composition (i.e., increase in fat mass and loss of muscle mass) triggered by profound hypogonadism during ADT have been implicated in the development of insulin resistance in prior studies21. Indeed, cytokines secreted by the adipocytes induce insulin resistance22 and parenchymal fat deposition in liver and skeletal muscles result in impaired insulin signaling23,24. Muscle atrophy and resulting reduced muscle capillarity, leads to reduced muscle glucose disposal and glycogen storage25,26. Insulin resistance is an independent risk factor for atherosclerosis and CVD, and a precursor to type 2 diabetes mellitus. Patients undergoing ADT have increased risk of myocardial infarction, stroke, ischemia-induced congestive heart failure, and peripheral vascular disease27–31, and CVD remains the predominant cause of death in this population32,33. Some patients undergoing ADT experience an accelerated course of CVD, as cardiovascular events have been observed within months of starting treatment7, implying that ensuing metabolic perturbations precipitate underlying atherosclerotic coronary disease26. Based on these observations, physicians are both concerned and cautious when contemplating starting ADT in men with established (or at high risk) of CVD, and often seek cardiac evaluation before treatment initiation34–36. However, these practice patterns are dictated by data from studies that had not rigorously excluded diabetes in patients starting ADT. In this respect, the findings of the present study are reassuring.
An increase in adipose tissue mass often leads to spillover of fat into parenchymal organs23, and deposition of fat in the liver37 and skeletal muscle38 triggers development of insulin resistance. Studies using Medicare data have shown that men undergoing ADT develop hepatic steatosis, the incidence of which increases with ADT duration39. These data prompted us to assess hepatic and intramyocellular fat with MRS during ADT. Although 24 weeks ADT was associated with a substantial increase in fat mass (3.7 kg), it did not result in parenchymal fat deposition.
Although this study was designed to elucidate the predominant site of insulin resistance during ADT, we found that insulin resistance remained unchanged in these participants. The likely reason for this finding is that unlike previous studies, we rigorously excluded men with underlying diabetes, applying all diagnostic criteria delineated by the American Diabetes Association, rendering this cohort metabolically healthier than previous cohorts. Additionally, we assessed insulin resistance using frequent sampling OGTT (a method that has been validated against the glucose clamp technique)13,14 whereas previous studies had relied on less precise measures such as serum insulin concentrations or HOMAIR.
The strengths of this study include inclusion of carefully selected treatment-naïve men who were eugonadal and did not have diabetes, use of frequent-sampling OGTT, assessment of parenchymal fat using MRS, and enrollment of a control group that allowed comparisons of metabolic changes over time. One limitation of the study is that we did not control for physical activity; however, due to ADT-induced fatigue, enrolled participants did not engage in structured exercises. Another limitation of the study includes relatively short follow-up duration; however, we chose this duration as most men with intermediate risk PCa generally receive ADT for 24 weeks. Previous cross-sectional data suggest that insulin resistance and glucose control worsen with ADT duration20; thus, it is conceivable that patients receiving ADT for longer than 24 weeks may still develop insulin resistance, predisposing them to increased cardiovascular risk. This question needs to be addressed in future studies.
In conclusion, administration of ADT for 24 weeks in men without diabetes did not worsen insulin resistance despite a substantial increase in fat mass. These findings have relevance for both physicians and their patients when determining treatment for PCa and suggest that a short course of ADT may not worsen metabolic risk in patients without pre-existing diabetes.
Acknowledgements:
The investigators are very thankful and indebted to the study participants who selflessly dedicated their time and effort to make this work possible. We also want to thank the staff of the Brigham and Women’s Hospital’s Center for Clinical Investigation for their hard work and diligence.
Funding:
National Cancer Institute (R01CA226211) and National Institute on Aging (K24AG070078).
Footnotes
Conflicts of Interest: None.
REFERENCES
- 1.Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023.CA Cancer J Clin. 2023;73:17–48. [DOI] [PubMed] [Google Scholar]
- 2.Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer.JAMA. 2005;294:238–44. [DOI] [PubMed] [Google Scholar]
- 3.Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83. [DOI] [PubMed] [Google Scholar]
- 4.Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581–8. [DOI] [PubMed] [Google Scholar]
- 5.Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996;39:1345–50. [DOI] [PubMed] [Google Scholar]
- 6.Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261–7. [DOI] [PubMed] [Google Scholar]
- 7.Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56. [DOI] [PubMed] [Google Scholar]
- 8.Klimis H, Pinthus JH, Aghel N, et al. The Burden of Uncontrolled Cardiovascular Risk Factors in Men with Prostate Cancer: A RADICAL-PC Analysis. JACC Cardio Oncol. 2023;5:70–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease.Nat Rev Endocrinol. 2017;13:572–587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia. 2008;51:130–8. [DOI] [PubMed] [Google Scholar]
- 11.Braga-Basaria M, Travison TG, Taplin ME, et al. Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023;18:e0281508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.ElSayed NA, Aleppo G, Aroda VR, et al. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023.Diabetes Care. 2023;46:S19–S40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70. [DOI] [PubMed] [Google Scholar]
- 14.Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89–94. [DOI] [PubMed] [Google Scholar]
- 15.Vogelzangs N, van der Kallen CJH, van Greevenbroek MMJ, et al. Metabolic profiling of tissue-specific insulin resistance in human obesity: results from the Diogenes study and the Maastricht Study. Int J Obes. 2020;44:1376–86. [DOI] [PubMed] [Google Scholar]
- 16.O’ Donovan SD, Lenz M, Goossens GH, et al. Improved quantification of muscle insulin sensitivity using oral glucose tolerance test data: the MISI Calculator. Sci Rep. 2019;9:1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. [DOI] [PubMed] [Google Scholar]
- 18.Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:S10–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8. [DOI] [PubMed] [Google Scholar]
- 20.Basaria S, Muller DC, Carducci MA, et al. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Arch Intern Med. 2007;167:612–3. [DOI] [PubMed] [Google Scholar]
- 21.Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14:204–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91. [DOI] [PubMed] [Google Scholar]
- 23.Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010;1801:209–14. [DOI] [PubMed] [Google Scholar]
- 24.Shulman GI. Ectopic fat in insulin resistance, dyslipidemia and cardiometabolic disease. N Engl J Med. 2014;371:1131–41. [DOI] [PubMed] [Google Scholar]
- 25.Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006; 91:3024–33. [DOI] [PubMed] [Google Scholar]
- 26.Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93:2042–9. [DOI] [PubMed] [Google Scholar]
- 27.Hu JC, Williams SB, O’Malley AJ, et al. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Nguyen PL, Chen MH, Beckman JA, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012;82:1411–6. [DOI] [PubMed] [Google Scholar]
- 30.Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866–73. [DOI] [PubMed] [Google Scholar]
- 31.Saigal CS, Gore JL, Krupski TL, et al. Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500. [DOI] [PubMed] [Google Scholar]
- 32.Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol. 2004;171:2285–90. [DOI] [PubMed] [Google Scholar]
- 33.Tsai HK, D’Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–24. [DOI] [PubMed] [Google Scholar]
- 34.Martín-Merino E, Johansson S, Morris T, García Rodríguez LA. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf. 2011;34:1061–77. [DOI] [PubMed] [Google Scholar]
- 35.Ziehr DR, Chen MH, Zhang D, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116:358–65. [DOI] [PubMed] [Google Scholar]
- 36.Levine GN, D’Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023–8. [DOI] [PubMed] [Google Scholar]
- 38.Muoio DM. Revisiting the connection between intramyocellular lipids and insulin resistance: a long and winding road. Diabetologia. 2012;55:2551–4. [DOI] [PubMed] [Google Scholar]
- 39.Gild P, Cole AP, Krasnova A, et al. Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018;200:573–581. [DOI] [PubMed] [Google Scholar]
